In the context of a Lanham Act case, CRA assessed whether market performance for a hospital-based pharmaceutical product was affected by alleged improper statements by a competitor. CRA’s causality analysis included consideration of other economic factors that affected product sales, including assessment of market preparation, launch, commercialization, and promotional efforts used to support the product that was allegedly affected by improper marketing support.
CRA earns widespread recognition across biggest competition cases for GCR Awards 2026
Charles River Associates achieved widespread recognition at the 2026 Global Competition Review Awards, with nominations spanning nearly every major competition